Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Oct 01, 2026
Mumbai (Maharashtra) [India], October 1: Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA) (BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October.
Read More ..